九典制藥(300705.SZ):2019年度淨利潤降23.5%至5506.59萬元 擬10派0.36元
格隆匯4月17日丨九典制藥(300705.SZ)披露2019年年度報告,實現營業收入9.24億元,同比增長15.31%;歸屬於上市公司股東的淨利潤5506.59萬元,同比下降23.50%;歸屬於上市公司股東的扣除非經常性損益的淨利潤4639.46萬元,同比下降31.16%;基本每股收益0.23元,擬向全體股東每10股派發現金紅利0.36元(含税)。
報告期內,經濟形勢整體下行,貿易摩擦不斷,醫藥工業營收增幅同比下跌。同時行業政策頻出,三醫聯動,醫改步入深水區,進入了新時代、新常態,集採擴圍、醫保支付目錄調整等政策持續加速推進,降藥價、促合理、提質量、強監管,給行業帶來了顛覆性的變化。就公司內部而言,公司將望城生產基地原料藥及藥用輔料產品及業務整體劃轉至九典宏陽,原輔料批文隨之轉移,相關產品重新備案、接受客户審計,給公司經營帶來了巨大壓力。
面對內外部形勢變更,公司管理團隊積極應對,主動作為,迎難而上,着力於新產品研發、市場開拓、新基地建設、降本增效,狠抓產品產業化,深化內部管理,基本完成了公司的全年目標任務。公司先後獲評國家級綠色工廠、湖南省製造業百強企業等。
報告期內,收入增長的主要原因在於公司不斷加大市場開拓力度,同時新產品逐步投入市場,產品收入實現穩健增長。歸屬於上市公司股東的淨利潤5506.59萬元,比上年同期下降23.50%,主要是公司銷售模式中合作經銷模式比例逐步加大,市場推廣費用增長較快,且公司為進一步提升核心競爭力,持續加大研發投入所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.